Researchers at the University of Illinois found that lunasin binds to a specific receptor in highly metastatic colon cancer cells, preventing them from attaching to the liver. Almost all colon cancer deaths involve the cancer spreading to the liver.
Specifically, combining lunasin with the chemotherapy drug oxaliplatin resulted in a six-fold reduction in the number of new tumor sites.
Related Articles on Colon Cancer:
High Levels of Alcohol Consumption Increase Risk of Colon Cancer
Study: MRI Helps Predict Survival of Rectal Cancer Patients
First Endoscopic Suturing Performed on Large Polyp Resection
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
